Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to assess safety, tolerability, preliminary efficacy, and PK of TAK-671 in participants with COVID-19.


Clinical Trial Description

The drug being tested in this study is called TAK-671. The study will evaluate the safety, tolerability and PK of TAK-671 in participants admitted to the hospital with a confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive test.

The study will enroll approximately 40 participants. Each cohort will have 20 participants. Participants will be randomly assigned (by chance, like flipping a coin) in a 3:1 ratio to receive TAK-671 or placebo in each cohort, which will remain undisclosed to the participant during the study (unless there is an urgent medical need):

- Cohort 1: TAK-671 Low Dose

- Cohort 2: TAK-671 High Dose

Enrollment in Cohort 2 will only begin once all 20 participants in Cohort 1 have reached Day 7 post dose and have received positive review from the internal review committee (IRC) and approval to continue enrollment. All participants will receive the standard of care along with the study treatment.

This multi-center trial will be conducted in the United States. The overall time to participate in this study is approximately 3 months. All participants will be followed up 28 days after the infusion. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04464460
Study type Interventional
Source Takeda
Contact
Status Withdrawn
Phase Phase 1
Start date September 25, 2020
Completion date October 30, 2020

See also
  Status Clinical Trial Phase
Completed NCT05768113 - LAEH Formulation Nasal Spray to Reduce Viral Load
Completed NCT04488588 - Survival and 30-days Hospital Outcome in COVID-19 Patients in Upper Egypt
Recruiting NCT05922865 - The Effect of Smart Sensor Combined With APP for Individualized Precise Exercise Training in Long Covid-19 N/A
Recruiting NCT04479293 - Post COVID-19 Functional Status in Egypt
Withdrawn NCT05112874 - ImmuneSense™ COVID-19 Cross-Reactivity Study
Completed NCT04999111 - A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2 Phase 2
Terminated NCT04369989 - Observational Study of COVID-19 Treatment Efficacy